Recent News Releases
For investor-related news, see our ASX releases here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Dec 3, 2016Global biotherapeutics leader CSL Behring today announced new results from its Phase III clinical development program evaluating IDELVION® [Coagulation Factor IX (Recombinant), Albumin Fusion Protein], the company’s novel, long-acting recombinant albumin fusion protein for the treatment of hemophilia B.
03 Dec 2016 Analysis of clinical trial efficacy results and estimated factor IX levels suggests that patients who maintain factor IX activity levels above 5 and 10 percent have significantly...
-
Dec 2, 2016CSL Behring’s RAPID Extension Study data confirms disease-modifying effect of Respreeza® in patients with AATD.
02 Dec 2016 Global biotherapeutics leader CSL Behring announced today that data from the RAPID Open Label Extension study, conducted in patients with alpha-1 antitrypsin deficiency (AATD),...
-
Nov 28, 2016
PDF VERSION OF PRESS RELEASE Back to overview of Press Release
-
Nov 24, 2016
PDF VERSION OF PRESS RELEASE Back to overview of Press Release
-
Nov 15, 2016AEGIS-1 Phase 2b study meets co-primary endpoints of hepatic and renal safety and demonstrates proof of mechanism - results were presented at AHA 2016.
15 Nov 2016 CSL Behring today announced positive results from AEGIS-I, a Phase 2b safety and proof of mechanism clinical study of CSL112, a novel apolipoprotein A-I (apoA-I) infusion therapy....
-
Nov 14, 2016Global biotherapeutics leader CSL Behring announced today that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorisation for AFSTYLA® [Recombinant Human Coagulation Factor VIII, Single Chain] for patients with haemophilia A.
14 Nov 2016 CHMP positive opinion moves AFSTYLA one step closer to approval in the European Union AFSTYLA is the first and only single-chain therapy for haemophilia A. The therapy has been...
-
Oct 27, 2016One of the world’s top specialty biotherapeutics companies, CSL Behring continues to introduce innovations to address unmet medical needs or enhance current treatments
27 Oct 2016 Marcum LLP and Philadelphia SmartCEO magazine have recognized CSL Behring with the 2016 Innovator Breakthrough Award for developing novel products that save lives and improve quality...
-
Oct 25, 2016
PDF VERSION OF PRESS RELEASE Back to overview of Press Release
-
Oct 7, 2016Many Rare Disease Patients Would Not Have Treatments Available to Them without an Adequate Supply of Human Plasma, and patients call plasma donors "heroes" for their lifesaving contributions.
07 Oct 2016 More than 1,000 plasma donations may be needed to treat one adult patient with a rare disease for a year During International Plasma Awareness Week, plasma donors are recognized by...
-
Oct 6, 2016
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Oct 3, 2016CSL Behring announced that the Australian Therapeutic Goods Administration (TGA) has approved IDELVION®[albutrepenonacog alfa] in patients with haemophilia B (congenital factor IX deficiency).
03 Oct 2016 IDELVION is a long-acting recombinant albumin fusion protein for children and adults with haemophilia B, and is the first CSL Behring recombinant factor product to receive TGA approval...
-
Sep 29, 2016Global biotherapeutics leader CSL Behring announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved IDELVION® [Albutrepenonacog Alfa], its innovative, long-acting albumin fusion protein linking recombinant coagulation factor IX with recombinant albumin for the prevention of bleeding tendency in patients with factor IX deficiency.
29 Sep 2016 IDELVION® delivers high-level protection from bleeds by maintaining factor IX activity levels at an average of 20 percent in patients treated prophylactically every 7-days and an...
-
Sep 21, 2016CSL Behring is proud to be a platinum sponsor of the 17th Biennial Meeting of the European Society for Immunodeficiencies (ESID) this week in Barcelona
21 Sep 2016 Hizentra® - the only 20% concentration SCIG with a proven track record of safety and efficacy for over 6 years; trusted by more than 18,000 patients and providers worldwide Privigen®...
-
Sep 16, 2016General Counsel Greg Boss of global biotherapeutics leader CSL Limited today accepted the World Recognition of Distinguished General Counsel from the Directors Roundtable in recognition of his professional accomplishments and passion for ethical leadership
16 Sep 2016 General Counsel Greg Boss of global biotherapeutics leader CSL Limited today accepted the World Recognition of Distinguished General Counsel from the Directors Roundtable in...
-
Sep 6, 2016CSL Behring is hosting an Expert Forum "Modifying Alpha-1 Antitrypsin Deficiency Related Emphysema" today during the 26th International Congress of the European Respiratory Society (ERS) in London.
06 Sep 2016 Global biotherapeutics leader CSL Behring will host an Expert Forum about Alpha-1 Antitrypsin Deficiency (AATD) today during the 26th International Congress of the European Respiratory...
-
Sep 2, 2016
PDF VERSION OF PRESS RELEASE Back to overview of Press Release
-
Sep 1, 2016
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Aug 30, 2016The U.S. Food and Drug Administration (FDA) has accepted CSL Behring’s application for its low volume subcutaneous (SC) C1-Esterase Inhibitor (C1-INH) Human replacement therapy for treating HAE. Upon FDA approval, CSL830 will be the first and only low volume, subcutaneous, prophylactic treatment option for HAE patients.
30 Aug 2016 CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s Biologics License Application (BLA) for its low-volume subcutaneous...
-
Aug 9, 2016
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Aug 4, 2016
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Jul 27, 2016CSL Behring today presented data from a Phase III pivotal study of AFSTYLA® [Antihemophilic Factor (Recombinant), Single Chain] in hemophilia A patients less than 12 years of age at the XXXII International Congress of the World Federation of Hemophilia (WFH) in Orlando, Fla.
27 Jul 2016 AFSTYLA prophylaxis and on-demand treatment demonstrated long-lasting hemostatic efficacy in pediatric patients with severe hemophilia A in phase III data presented Patients using AFSTYLA
-
Jul 26, 2016CSL Behring today announced new data from its Phase III PROLONG-9FP clinical development program evaluating IDELVION® [Coagulation Factor IX (Recombinant), Albumin Fusion Protein], the company’s novel, long-acting recombinant albumin fusion protein for treating hemophilia B.
26 Jul 2016 New analyses from global PROLONG-9FP clinical development program show: Adult patients prolonged dosing interval to up to 21 days for routine prophylaxis in extension study Mean...
-
Jul 25, 2016CSL Behring today announced that the company has named five recipients of the 2016 CSL Behring Professor Heimburger Award for coagulation research at the XXXII International Congress of the World Federation of Hemophilia (WFH) in Orlando, Fla.
25 Jul 2016 Five start-up grants totaling $110,000 awarded by CSL Behring The 2016 CSL Behring Professor Heimburger Awards demonstrate the global biotherapeutics leader’s 100-year promise to...
-
Jul 21, 2016
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Jul 19, 2016CSL Behring announced today that it will present new data from its recombinant coagulation factor development programs at the XXXII International Congress of the World Federation of Hemophilia (WFH) in Orlando, Fla., July 24 – 28, 2016.
19 Jul 2016 Abstracts include pivotal efficacy and safety data for IDELVION for hemophilia B and AFSTYLA for hemophilia A; AFSTYLA and IDELVION demonstrate CSL Behring’s promise to develop and...
-
Jul 18, 2016CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has approved the use of Berinert [C1 Esterase Inhibitor (Human)], its therapy for treating Hereditary Angioedema (HAE) attacks, for use in pediatric patients.
18 Jul 2016 CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has approved the use of Berinert [C1 Esterase Inhibitor (Human)], its therapy for treating Hereditary...
-
Jun 23, 2016CSL Behring announced today at the Peripheral Nerve Society’s Inflammatory Neuropathy Consortium (INC) meeting at the University of Glasgow, Scotland, the winners of its annual Interlaken Leadership Awards.
23 Jun 2016 CSL Behring announced today at the Peripheral Nerve Society’s Inflammatory Neuropathy Consortium (INC) meeting at the University of Glasgow, Scotland, the winners of its annual...
-
Jun 20, 2016Driven by its promise to save lives, CSL Behring announced today that AFSTYLA® [Antihemophilic Factor (Recombinant), Single Chain], its novel long-lasting recombinant factor VIII single-chain therapy for adults and children with hemophilia A, is now available nationwide.
20 Jun 2016 AFSTYLA is the first and only single-chain product for hemophilia A, specifically designed for long-lasting protection from bleeds with twice-weekly dosing available In clinical...
-
May 26, 2016CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has approved AFSTYLA® [Antihemophilic Factor (Recombinant), Single Chain], its novel long-lasting recombinant factor VIII single-chain therapy for adults and children with hemophilia A.
26 May 2016 AFSTYLA is the first and only single-chain product for hemophilia A, specifically designed for long-lasting protection from bleeds with twice-weekly dosing available In clinical...
-
May 24, 2016
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
May 24, 2016
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
May 23, 2016
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
May 16, 2016CSL Behring supports HAE Day through our continued partnership with HAEi & global awareness event sponsorships.
16 May 2016 CSL Behring joins the global HAE community today in recognition of the fifth annual hae day :-), an initiative led by HAEi, the international patient organization for C1-inhibitor...
-
May 13, 2016Philadelphia Alliance for Capital and Technologies (PACT), an affiliate of the Greater Philadelphia Chamber of Commerce, has recognized CSL CEO and Managing Director Paul Perreault with its 2016 Healthcare CEO Award.
13 May 2016 Philadelphia Alliance for Capital and Technologies (PACT), an affiliate of the Greater Philadelphia Chamber of Commerce, has recognized CSL CEO and Managing Director Paul Perreault...
-
May 11, 2016
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
May 11, 2016CSL Behring announced today it has been granted seven years of marketing exclusivity by the U.S. Food and Drug Administration (FDA) for IDELVION® [Coagulation Factor IX (Recombinant), Albumin Fusion Protein].
11 May 2016 CSL Behring announced today it has been granted seven years of marketing exclusivity by the U.S. Food and Drug Administration (FDA) for IDELVION® [Coagulation Factor IX (Recombinant),...
-
May 11, 2016CSL Behring announced today that the European Commission has approved IDELVION® [albutrepenonacog alfa], its innovative, long-acting albumin fusion protein linking recombinant coagulation factor IX with recombinant albumin for the treatment and prophylaxis of bleeding in patients with hemophilia B (congenital factor IX deficiency).
11 May 2016 In clinical trials, IDELVION maintained factor IX activity levels above 5 percent over 14 days in the majority of patients, resulting in a median annualized spontaneous bleeding rate...
-
May 10, 2016
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
May 10, 2016
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
May 9, 2016
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
May 3, 2016In a keynote address on patient-centric leadership at the eyeforpharma Philadelphia Summit, CSL Chief Executive Officer and Managing Director Paul Perreault called on fellow industry leaders to do much more to connect with and learn from patients.
03 May 2016 A successful Pharma of the future requires a much different, authentic form of patient engagement Patient-centric leadership is fully embedded across CSL’s organization since its...
-
Apr 28, 2016
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Apr 25, 2016CSL Behring today commemorated 100 years of developing and delivering innovative therapies to treat people with life-threatening medical conditions and help them live full lives.
25 Apr 2016 Locally, Company donates 100 trees to Valley Forge National Historical Park to mark centennial anniversary Shipment is a part of CSL Behring’s three year promise to provide more than...
-
Apr 25, 2016
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Apr 13, 2016“Treatment for All is the Vision for All” is the World Federation of Hemophilia’s (WFH) global message for World Hemophilia Day this year (April 17, 2016). Demonstrating that purpose, the WFH and global biotherapeutics leader CSL Behring announced today that CSL Behring has shipped more than 1.5 million international units (IUs) of its specialty biotherapeutics to treat hemophilia A and/or von Willebrand Disease to the WFH Global Alliance for Progress (GAP) Program and other WFH programs.
13 Apr 2016 More than 1.5 million international units (IUs) of treatments for Hemophilia A and/or von Willebrand Disease shipped in advance of World Hemophilia Day Shipment is a part of CSL Behring’
-
Apr 5, 2016CSL Behring announced today that the European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) supports maintaining the orphan designation for IDELVION® [Coagulation Factor IX (Recombinant), Albumin Fusion Protein]. IDELVION® is CSL Behring’s novel, long-acting recombinant albumin fusion protein for treating hemophilia.
05 Apr 2016 CSL Behring announced today that the European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) supports maintaining the orphan designation for IDELVION®...
-
Mar 21, 2016CSL Behring announced today that IDELVION® [Coagulation Factor IX (Recombinant), Albumin Fusion Protein], its novel, long-acting recombinant albumin fusion protein for treating hemophilia B, is now available nationwide.
21 Mar 2016 In clinical trials, IDELVION maintained factor IX activity levels above 5 percent over 14 days, resulting in a median annualized spontaneous bleeding rate (AsBR) of 0.00 IDELVION, CSL...
-
Mar 15, 2016A new webinar series addresses the unique needs of young adults living with Primary Immunodeficiency at a critical time when they are transitioning from teen to adulthood and taking responsibility for their own care.
15 Mar 2016 In honor of the upcoming World Primary Immunodeficiencies (PI) Week, CSL Behring is proud to sponsor Immune Deficiency Foundation’s new PI Voices, Young Adult Webinar Series. The...
-
Mar 15, 2016
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Mar 9, 2016CSL Behring Awards LEAD Grants to Help Rare Disease Patient Groups Achieve Their Advocacy ObjectivesPatients are their own most important advocates, and global biotherapeutics leader CSL Behring has renewed its commitment to helping empower them with the announcement of the latest round of LEAD Grant awards. CSL Behring established the LEAD grant program in 2008 to help support the important advocacy work of patient groups in tackling complex legislative and public policy issues.
09 Mar 2016 Patients are their own most important advocates, and global biotherapeutics leader CSL Behring has renewed its commitment to helping empower them with the announcement of the latest...